Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

Clinical trial NCT07772024 · RECRUITING

Trial details

NCT number: NCT07772024
Sponsor: CellCentric Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma Refractory Multiple Myeloma in Relapse

Start date: 2026-08-01
Primary completion: 2029-11-01
Enrollment: 450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.